Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 12.1. Antianginal medicines |
Others observations: Includes metoprolol and carvedilol as alternatives. |
| WHO Model List of Essential Medicines (2021) | 12.2. Antiarrhythmic medicines |
Others observations: Includes metoprolol and carvedilol as alternatives. |
| WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: atenolol, carvedilol, metoprolol. Atenolol should not be used as a first-line agent in uncomplicated hypertension in patients > 60 years. |
| WHO Model List of Essential Medicines (2021) | 12.4. Medicines used in heart failure |
Others observations: Includes metoprolol and carvedilol as alternatives. |
| PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines |
Others observations: Metoprolol and carvedilol as alternatives. |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 12.1. Antianginal medicines |
Others observations: Includes metoprolol and carvedilol as alternatives. |
| WHO Model List of Essential Medicines (2021) | 12.2. Antiarrhythmic medicines |
Others observations: Includes metoprolol and carvedilol as alternatives. |
| WHO Model List of Essential Medicines (2021) | 12.3. Antihypertensive medicines |
Others observations: Therapeutic alternatives: atenolol, carvedilol, metoprolol. Atenolol should not be used as a first-line agent in uncomplicated hypertension in patients > 60 years. |
| WHO Model List of Essential Medicines (2021) | 12.4. Medicines used in heart failure |
Others observations: Includes metoprolol and carvedilol as alternatives. |
| PAHO Strategic Fund Medicine List | 6.1. Antihypertensive medicines |
Others observations: Metoprolol and carvedilol as alternatives. |
| List | Section | Observation |
|---|---|---|
| Peru | 12.4 Medications Used in Cardiac Insufficiency | No observations |